| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,459,164 | -3,321,491 |
| Stock-based compensation expense | 1,755,218 | 1,364,378 |
| Other receivables | - | 0 |
| Unrealized gain on short-term investments | 176,056 | - |
| Trade accounts payable and accrued expenses | -639,424 | -424,891 |
| Prepaid expenses | 7,206 | 47,674 |
| Net cash flows from operating activities | -3,526,632 | -2,429,678 |
| Offering costs | 134,049 | 21,480 |
| Proceeds from stock option exercises | 297,792 | - |
| Proceeds from sales of common stock | 3,171,497 | 348,702 |
| Net cash flows provided by financing activities | 3,335,240 | 327,222 |
| Net change in cash | -191,392 | -2,102,456 |
| Cash and cash equivalents at beginning of period | 2,832,931 | - |
| Cash and cash equivalents at end of period | 2,641,539 | - |
MIRA PHARMACEUTICALS, INC. (MIRA)
MIRA PHARMACEUTICALS, INC. (MIRA)